The data are consistent with our previous analyses by semiquantitative mRNA in situ hybridisation, which suggested that EIF3S3 is expressed more in hormone-refractory prostate carcinomas than in BPH (Nupponen et al, 1999). This evidence concerns the gene EIF3H and benign prostatic hyperplasia.